Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular RiskEugene Han, Seung Up Kim, Ji Hoe Heo et al.|The American Journal of Gastroenterology|2020Cited by 112
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Seng Gee Lim, Wei Zhao et al.|Clinical Gastroenterology and Hepatology|2019Cited by 111
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3Anjali Sibley, Samir M. Fakhry, Kwang‐Hyub Han et al.|Journal of Viral Hepatitis|2015Cited by 77
Autoimmune liver diseases in the Asia–Pacific region: Proceedings of APASL symposium on AIH and PBC 2016Atsushi Tanaka, Hajime Takikawa, Xiong Ma et al.|Hepatology International|2016Cited by 55